CTLT - Catalent, Inc.

NYSE - NYSE Delayed Price. Currency in USD
53.15
-2.09 (-3.78%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close55.24
Open54.94
Bid43.00 x 800
Ask53.37 x 1000
Day's Range52.97 - 55.56
52 Week Range29.23 - 58.38
Volume880,582
Avg. Volume722,789
Market Cap7.745B
Beta (3Y Monthly)1.77
PE Ratio (TTM)50.81
EPS (TTM)1.05
Earnings DateAug 27, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est53.44
Trade prices are not sourced from all markets
  • Read This Before Judging Catalent, Inc.'s (NYSE:CTLT) ROE
    Simply Wall St.

    Read This Before Judging Catalent, Inc.'s (NYSE:CTLT) ROE

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

  • Earnings Preview: Catalent (CTLT) Q4 Earnings Expected to Decline
    Zacks

    Earnings Preview: Catalent (CTLT) Q4 Earnings Expected to Decline

    Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Medtronic (MDT) to Post Q1 Earnings: Will RTG Aid the Stock?
    Zacks

    Medtronic (MDT) to Post Q1 Earnings: Will RTG Aid the Stock?

    Medtronic (MDT) is encouraged by robust and consistent constant currency growth in the RTG business over the last few quarters.

  • Medtronic (MDT) to Report Q1 Earnings: What's in Store?
    Zacks

    Medtronic (MDT) to Report Q1 Earnings: What's in Store?

    Medtronic's (MDT) successful execution of growth policies should aid earnings results in the fiscal first quarter.

  • Tilray (TLRY) to Report Q2 Earnings: What's in the Cards?
    Zacks

    Tilray (TLRY) to Report Q2 Earnings: What's in the Cards?

    Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports second-quarter 2019 results.

  • Why Catalent (CTLT) is Poised to Beat Earnings Estimates Again
    Zacks

    Why Catalent (CTLT) is Poised to Beat Earnings Estimates Again

    Catalent (CTLT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Business Wire

    Catalent, Inc. Announces Fourth Quarter Fiscal Year 2019 Earnings Conference Webcast

    Catalent, Inc. (CTLT) (“Catalent”), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced that it will release financial results for the fourth quarter of fiscal year 2019 ended June 30, 2019, before the market open on Tuesday, August 27, 2019. Catalent invites all interested parties to listen to the webcast, which will be accessible through Catalent’s website at http://investor.catalent.com. A supplemental slide presentation will also be available in the “Investors” section of Catalent’s website prior to the start of the webcast.

  • CTLT vs. ZTS: Which Stock Is the Better Value Option?
    Zacks

    CTLT vs. ZTS: Which Stock Is the Better Value Option?

    CTLT vs. ZTS: Which Stock Is the Better Value Option?

  • Business Wire

    Catalent Extends Global Commercial Spray Drying Capabilities in Europe

    Catalent, Inc. (CTLT), the leading global provider of advanced delivery technologies, and development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that it has significantly expanded the capacity of its global spray drying operations through an agreement with Sanofi Active Ingredient Solutions, an industrial platform of Sanofi, under which Sanofi will provide Catalent with access to spray drying manufacturing services for Catalent’s customers at Sanofi’s Haverhill, U.K. facility.

  • Business Wire

    Catalent Announces Pricing of Private Offering of Senior Unsecured Notes Due 2027

    Catalent, Inc. (“Catalent”) (CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the “Operating Subsidiary”), priced a private offering (the “Private Offering”) of $500.0 million in aggregate principal amount of 5.00% senior unsecured notes due 2027 (the “Notes”) at par. The Operating Subsidiary intends to use the net proceeds from the Private Offering to (i) repay in full the outstanding borrowings under its U.S. dollar-denominated term loans that mature in May 2024 under its senior secured credit facilities, plus any accrued and unpaid interest thereon, (ii) pay related fees and expenses and (iii) provide cash on its balance sheet for general corporate purposes.

  • Business Wire

    Catalent Announces Launch of Private Offering of $500 Million of Senior Unsecured Notes Due 2027

    Catalent, Inc. (“Catalent”) (CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the “Operating Subsidiary”), intends to offer, subject to market and other conditions, $500 million in aggregate principal amount of senior unsecured notes due 2027 (the “Notes”) in a private offering (the “Private Offering”) that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Operating Subsidiary intends to use the net proceeds from the Private Offering to (i) repay in full the outstanding borrowings under its U.S. dollar-denominated term loans that mature in May 2024 under its senior secured credit facilities, plus any accrued and unpaid interest thereon, (ii) pay related fees and expenses, and (iii) provide cash on its balance sheet for general corporate purposes.

  • Catalent (CTLT) Upgraded to Buy: What Does It Mean for the Stock?
    Zacks

    Catalent (CTLT) Upgraded to Buy: What Does It Mean for the Stock?

    Catalent (CTLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

  • Business Wire

    Catalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy

    Bristol-Myers Squibb Company (BMY) and Catalent, Inc. (CTLT), today announced that Catalent has agreed to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy. Catalent is the leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products.

  • Business Wire

    Catalent, Inc. to Present at the Jefferies Healthcare Conference

    Catalent, Inc. , the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Wetteny Joseph, Senior Vice President & Chief Financial Officer, will present at the Jefferies Healthcare Conference at 3:00 p.m.

  • Catalent Acquires Gene Therapy Leader Paragon Bioservices
    Zacks

    Catalent Acquires Gene Therapy Leader Paragon Bioservices

    Catalent (CTLT) acquires gene therapy leader Paragon Bioservices for $1.2 billion.

  • Business Wire

    Catalent Completes Acquisition of Gene Therapy Leader Paragon Bioservices, Inc. for $1.2 Billion

    Catalent, Inc. (CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has completed the $1.2 billion acquisition of Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies. With the addition of Paragon’s specialized expertise in adeno-associated virus (AAV) vectors, the most commonly used vector to deliver DNA to cells, Catalent is positioned to capitalize on strong industry tailwinds in the potentially $40 billion addressable market for gene therapies.

  • Thomson Reuters StreetEvents

    Edited Transcript of CTLT earnings conference call or presentation 7-May-19 12:15pm GMT

    Q3 2019 Catalent Inc Earnings Call

  • Catalent Inc (CTLT) Q3 2019 Earnings Call Transcript
    Motley Fool

    Catalent Inc (CTLT) Q3 2019 Earnings Call Transcript

    CTLT earnings call for the period ending March 31, 2019.

  • Catalent (CTLT) Surpasses Q3 Earnings Estimates
    Zacks

    Catalent (CTLT) Surpasses Q3 Earnings Estimates

    Catalent (CTLT) delivered earnings and revenue surprises of 8.89% and -4.14%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Catalent, Inc. Reports Third Quarter Fiscal 2019 Results

    SOMERSET, N.J.-- -- Q3'19 revenue of $617.5 million decreased 2% as-reported, but increased 2% in constant currency, from Q3'18, while Q3'19 YTD revenue of $1,792.3 million increased 1% as-reported, or 3% in constant currency, from the prior-year period. Double-digit organic segment EBITDA growth within Biologics and Specialty Drug Delivery, Oral Drug Delivery and Clinical Supply Services segments; ...

  • Catalent (CTLT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
    Zacks

    Catalent (CTLT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • CNW Group

    Global Cellulite Treatments Market Could Exceed $1.4 Billion by 2026

    PALM BEACH, Florida, April 18, 2019 /CNW/ -- The global cellulite market and its largest segment, the non-invasive treatment sector, are both expected to grow at a healthy rate. A recent industry report on the entire cellulite market (from Transparency Market Research) projected that: "The global cellulite treatment market was valued at around US$ 619.2 Million in 2017 and is anticipated to reach US$ 1,438.5 Million by 2026, expanding at a CAGR of 10.1% from 2018 to 2026. "A report on the non-invasive sector (from Future Market Insights) had an even higher projection: "The market for non-invasive treatment is expected to reach a value of over US$ 1,900 Million by the end of 2028, growing at a robust CAGR of 8.0% during the forecast period."  The Transparency report continued: "Technological advancements have and are expected to continue to increase the efficacy and ease of usage of esthetic products.

  • CNBC

    Stocks making the biggest moves premarket: Goldman Sachs, CVS, Best Buy, Facebook & more

    Check out the companies making headlines before the bell: Goldman Sachs GS — The investment bank reported quarterly profit of $5.71 per share , beating the consensus estimate of $4.89. Revenue fell short of forecasts, however.

  • Business Wire

    Catalent to Acquire Gene Therapy Leader Paragon Bioservices, Inc. for $1.2 Billion

    Catalent, Inc. (CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies, today announced they have entered into a definitive agreement under which Catalent will acquire Paragon for $1.2 billion. “Paragon’s unparalleled expertise in the rapidly growing market of gene therapy manufacturing will be a transformative addition to our business that we believe will accelerate our long-term growth.